Feature | Heart Valve Technology | April 09, 2020

Transcatheter Tricuspid Valve Repair Clip Device Cleared in Europe

Abbott's TriClip becomes first device of its kind to receive CE mark 

Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European CE mark clearance as a non-surgical treatment for people with a tricuspid valve regurgitation (TR). 

April 9, 2020 — Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European CE mark clearance as a non-surgical treatment for people with a tricuspid valve regurgitation (TR). 

The device is an iteration of the of Abbott's highly successful MitraClip used for transcatheter mitral valve repair (TMVR). It is the first minimally invasive, clip-based tricuspid valve repair device to be commercially available in the world. It is the second tricuspid valve repair device cleared for use in Europe, following the 2018 approval of the Edwards Lifesciences Cardioband Tricuspid Valve Reconstruction System.

The TriClip procedure repairs the tricuspid valve without the need for open-heart surgery. The device is delivered to the heart through the femoral vein in the leg and works by clipping together a portion of the leaflets of the tricuspid valve to reduce the backflow of blood. This approach allows the heart to pump blood more efficiently, relieving symptoms of TR and improving a person's quality of life.

"Patients suffering from severe tricuspid regurgitation are extremely ill and have very few treatment options," said Georg Nickenig, M.D., Ph.D., professor and chief, Department of Cardiology, University Hospital, Bonn, Germany, and lead investigator of the TRILUMINATE trial,[1] which generated strong data that helped lead to the CE mark of TriClip. "Abbott's TriClip could profoundly impact how physicians treat these patients. The therapy is backed by data proving safety and performance, durability, and improved patient quality of life."  

The CE mark for TriClip follows positive six-month data from Abbott's pivotal TRILUMINATE study examining edge-to-edge repair technique using TriClip, which was published in The Lancet in November 2019. The study demonstrated that TriClip reduced severity of TR and was associated with strong improvement in functional capacity and in quality of life at six months.

TriClip builds upon the proven success of Abbott's MitraClip device, which treats people with leaky mitral valves, or mitral regurgitation (MR). TriClip leverages the same clip-based technology as MitraClip but has a differentiated delivery system designed specifically for delivery to the tricuspid valve. A new, steerable guiding catheter system adapts to the right side of the heart, where the tricuspid valve resides, enabling the physician to effectively grasp and clip the leaflets of the tricuspid valve. Additionally, the TriClip device is available in two different sizes (NT and XT) to accommodate different patient anatomies.

The MitraClip system is the first transcatheter mitral valve therapy with more than 16 years of clinical experience and proven safety, survival and durable clinical outcomes. More than 100,000 patients have been treated worldwide with the device. 

About Tricuspid Valve Regurgitation

The tricuspid valve, often referred to as the "forgotten heart valve," has three leaflets that control the flow of blood between the two chambers on the right side of the heart. When those leaflets do not close properly, blood can flow in the reverse direction – known as regurgitation – forcing the heart to work harder. When left untreated, TR can lead to conditions such as atrial fibrillation, heart failure, and ultimately, death. The condition is difficult to treat, however, and options for patients have historically been extremely limited. People with TR are typically older and suffer from multiple co-morbidities, making open-heart surgery a high-risk procedure.[2]

The European approval comes on the heals of CE mark in January for the Tendyne for mitral valve replacement, the first commercially approved transcatheter mitral valve in the world. Read the article World's First Transcatheter Mitral Valve Approved in Europe.

For U.S. important safety information on MitraClip, visit: https://www.structuralheartsolutions.com/us/mitraclip-isi.

The TriClip Transcatheter Tricuspid Valve Repair System is an investigational device only in the U.S.

The Tendyne Transcatheter Mitral Valve Implantation System is an investigational device only in the U.S.

Related Transcatheter Tricuspid Valve Repair Content:

TriClip Device For Tricuspid Regurgitation Effective at One Year in TRILUMINATE Study

8 Cardiovascular Technologies to Watch in 2020

Abbott Launches Pivotal Trial of TriClip Tricuspid Valve Repair System

VIDEO: Tricuspid Device Clinical Trial Overview — Interview with Ori Ben-Yehuda, M.D.

Abbott Tricuspid Valve Repair System Reduces Tricuspid Regurgitation at 30 Days

VIDEO: Tricuspid Valve Imaging and Interventions Developing Hand-in-hand — Interview with Rebecca Hahn, M.D.,

Advances in Transcatheter Tricuspid Valve Technologies

Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial

 

References:

1. Georg Nickenig, Marcel Weber, Philipp Lurz, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. The Lancet. Vol 394, issue 10213, P2002-2011, Nov 30, 2019. DOI:https://doi.org/10.1016/S0140-6736(19)32600-5.

2. Topilski Y. Tricuspid valve regurgitation: epidemiology and pathophysiology. Minerva Cardioangiologica 2018 Mar 28 DOI: 10.23736/S0026-4725.18.04670-4).

Related Content

Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.